TOP TEN perturbations for Q96P31 (Homo sapiens)

Organism: Homo sapiens
Gene: Q96P31
Selected probe(set): 231093_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q96P31 (231093_at) across 5392 perturbations tested by GENEVESTIGATOR:

DLBCL study 1 (activated B-cell like; na?ve-like) / DLBCL study 1 (activated B-cell like; centroblast-like)

Relative Expression (log2-ratio):-5.851571
Number of Samples:2 / 3
Experimental DLBCL study 1 (activated B-cell like; na?ve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; centroblast-like)
Centroblast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-5.57137
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

DLBCL study 1 (activated B-cell like; unclassified) / DLBCL study 1 (activated B-cell like; na?ve-like)

Relative Expression (log2-ratio):5.2524996
Number of Samples:11 / 2
Experimental DLBCL study 1 (activated B-cell like; unclassified)
Unclassified B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; na?ve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

DLBCL study 1 (activated B-cell like; plasmablast-like) / DLBCL study 1 (activated B-cell like; na?ve-like)

Relative Expression (log2-ratio):4.8677998
Number of Samples:12 / 2
Experimental DLBCL study 1 (activated B-cell like; plasmablast-like)
Plasmablast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; na?ve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):4.6702385
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

Sjogren's syndrome study 2 (pSS) / Sjogren's syndrome study 2 (non-pSS)

Relative Expression (log2-ratio):4.5441236
Number of Samples:7 / 14
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSSS). Patients were at least 21 years old.
Control Sjogren's syndrome study 2 (non-pSS)
Incisional biopsy of one parotid gland of patients with Sicca-syndrome who did not fulfill the 2002 AECG criteria for primary Sjogren's syndrome (non-pSS Sicca). Patients were at least 21 years old.

Sjogren's syndrome study 1 (advanced) / normal minor salivary gland tissue

Relative Expression (log2-ratio):4.540062
Number of Samples:2 / 4
Experimental Sjogren's syndrome study 1 (advanced)
Whole minor salivary gland samples of patients with advanced Sjogren's syndrome.
Control normal minor salivary gland tissue
Whole minor salivary gland samples from non-Sjogren's syndrome control subjects.

memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)

Relative Expression (log2-ratio):-4.4025116
Number of Samples:6 / 6
Experimental memory B cell study 1 (CD27high)
CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control memory B cell study 1 (undivided)
CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

DLBCL study 1 (activated B-cell like; na?ve-like) / DLBCL study 1 (activated B-cell like; centrocyte-like)

Relative Expression (log2-ratio):-4.364235
Number of Samples:2 / 8
Experimental DLBCL study 1 (activated B-cell like; na?ve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; centrocyte-like)
Centrocyte B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

Sjogren's syndrome study 2 (pSS) / normal parotid gland tissue

Relative Expression (log2-ratio):4.060501
Number of Samples:7 / 9
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSSS). Patients were at least 21 years old.
Control normal parotid gland tissue
Samples taken from the dorsal caudal lobe of the parotid gland from control subjects that were at least 21 years old. Samples were harvested during surgery for oral or oropharyngeal squamous cell carcinoma. Histopathologic evaluation of parotid tissue from controls revealed no carcinoma